223 related articles for article (PubMed ID: 12570114)
1. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.
Di Marco F; Milic-Emili J; Boveri B; Carlucci P; Santus P; Casanova F; Cazzola M; Centanni S
Eur Respir J; 2003 Jan; 21(1):86-94. PubMed ID: 12570114
[TBL] [Abstract][Full Text] [Related]
2. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
4. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
5. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
9. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
10. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD.
Man WD; Mustfa N; Nikoletou D; Kaul S; Hart N; Rafferty GF; Donaldson N; Polkey MI; Moxham J
Thorax; 2004 Jun; 59(6):471-6. PubMed ID: 15170026
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
12. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
13. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
[TBL] [Abstract][Full Text] [Related]
14. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
Cazzola M; Santangelo G; Piccolo A; Salzillo A; Matera MG; D'Amato G; Rossi F
Pulm Pharmacol; 1994 Apr; 7(2):103-7. PubMed ID: 7915921
[TBL] [Abstract][Full Text] [Related]
15. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
Kottakis J; Cioppa GD; Creemers J; Greefhorst L; Lecler V; Pistelli R; Overend T; Till D; Rapatz Gn; Le Gros V; Bouros D; Siafakas N
Can Respir J; 2002; 9(2):107-15. PubMed ID: 11972164
[TBL] [Abstract][Full Text] [Related]
16. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
17. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
18. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.
Belman MJ; Botnick WC; Shin JW
Am J Respir Crit Care Med; 1996 Mar; 153(3):967-75. PubMed ID: 8630581
[TBL] [Abstract][Full Text] [Related]
19. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
Cazzola M; Paggiaro P; Palange P; Bjermer L; Ausin P; Carlsson LG; Ekelund J; Lotvall J
Clin Drug Investig; 2012 Mar; 32(3):147-55. PubMed ID: 22235841
[TBL] [Abstract][Full Text] [Related]
20. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
